Abstract | OBJECTIVE: METHODS: This post hoc analysis included patients with T2DM from 3 randomized, double-blind, placebo-controlled pivotal studies who received metformin as part of their background antidiabetes therapy. In the pivotal studies, patients with T2DM were randomly assigned to receive colesevelam HCl (3.75 g/d) or placebo added to existing metformin (26 weeks), sulfonylurea (26 weeks), or insulin (16 weeks) monotherapy or combination therapy, wherein the combination therapies may have included metformin. RESULTS: CONCLUSION:
|
Authors | Harold E Bays |
Journal | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
(Endocr Pract)
2011 Nov-Dec
Vol. 17
Issue 6
Pg. 933-8
ISSN: 1934-2403 [Electronic] United States |
PMID | 21856592
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Apolipoprotein A-I
- Apolipoproteins B
- Cholesterol, LDL
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Sulfonylurea Compounds
- hemoglobin A1c protein, human
- Allylamine
- Metformin
- Cholesterol
- Colesevelam Hydrochloride
|
Topics |
- Aged
- Allylamine
(adverse effects, analogs & derivatives, therapeutic use)
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Apolipoprotein A-I
(blood)
- Apolipoproteins B
(blood)
- Cholesterol
(blood)
- Cholesterol, LDL
(blood)
- Colesevelam Hydrochloride
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Double-Blind Method
- Drug Therapy, Combination
(adverse effects)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypercholesterolemia
(prevention & control)
- Hyperglycemia
(prevention & control)
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Insulin
(therapeutic use)
- Intention to Treat Analysis
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Patient Dropouts
- Sulfonylurea Compounds
(therapeutic use)
|